By Marie Rosenthal
The FDA approved siponimod (Mayzent, Novartis) tablets to treat adults with relapsing forms of multiple sclerosis (MS), including secondary progressive MS (SPMS) with active disease, relapsing-remitting MS (RRMS) and clinically isolated syndrome.
SPMS is a debilitating form of MS characterized by progressive and irreversible neurologic disability.